Forest/Lipha Acamprosate Indication Should Be Limited To Abstinent Patients
Executive Summary
Forest/Lipha's acamprosate should be limited to patients who are abstinent from alcohol prior to taking the drug, FDA's Psychopharmacologic Drugs Advisory Committee suggested May 10